Pfizer Oncology is pleased to announce that the FDA has updated the Prescribing Information for BRAFTOVI® (encorafenib) on February 24, 2026 to include new data with an expanded indication. The following information is available for State Society review:
BRAFTOVI Full Prescribing Information including Medication Guide